Concepedia

Kristen Chevalier

KC

Statistics

Publications

9

Citations

902

H-Index

9

Active since

2009

Affiliations

Janssen (United States)(Current)

Springhouse

Johnson & Johnson (United States)

Genmab (Netherlands)

Kristen Chevalier is an author at Janssen (United States) specializing in pharmacology, drug discovery, and medicine.

Publications per year

2009–2021

9

Publications

9

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

Sheri L. Moores, Mark L. Chiu, Barbara S. Bushey et al. · Cancer Research · 2016 · 283 citations

, , +17

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier et al. · Molecular Cancer Therapeutics · 2020 · 201 citations · Full text

, , +17

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Joost Neijssen, Rosa M. F. Cardoso, Kristen Chevalier et al. · Journal of Biological Chemistry · 2021 · 159 citations · Full text

, , +17

Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist

PR Wade, JM Palmer, Sandra McKenney et al. · British Journal of Pharmacology · 2012 · 121 citations · Full text

, , +8

Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity

John D. Douglass, Yin Zhou, Amy Wu et al. · Journal of Lipid Research · 2015 · 60 citations · Full text

, , +16

1–5 of 9